Abstract | OBJECTIVES: DESIGN: Retrospective matched cohort study. SETTING: Four acute regional hospitals in Hong Kong. PATIENTS AND METHODS: RESULTS: The addition of lopinavir/ ritonavir as initial treatment was associated with a reduction in the overall death rate (2.3%) and intubation rate (0%), when compared with a matched cohort who received standard treatment (15.6% and 11.0% respectively, P<0.05) and a lower rate of use of methylprednisolone at a lower mean dose. The subgroup who had received lopinavir/ ritonavir as rescue therapy, showed no difference in overall death rate and rates of oxygen desaturation and intubation compared with the matched cohort, and received a higher mean dose of methylprednisolone. CONCLUSION: The addition of lopinavir/ ritonavir to a standard treatment protocol as an initial treatment for severe acute respiratory syndrome appeared to be associated with improved clinical outcome. A randomised double-blind placebo-controlled trial is recommended during future epidemics to further evaluate this treatment.
|
Authors | K S Chan, S T Lai, C M Chu, E Tsui, C Y Tam, M M L Wong, M W Tse, T L Que, J S M Peiris, J Sung, V C W Wong, K Y Yuen |
Journal | Hong Kong medical journal = Xianggang yi xue za zhi
(Hong Kong Med J)
Vol. 9
Issue 6
Pg. 399-406
(Dec 2003)
ISSN: 1024-2708 [Print] China |
PMID | 14660806
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antiviral Agents
- Pyrimidinones
- Lopinavir
- Ritonavir
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antiviral Agents
(therapeutic use)
- Drug Therapy, Combination
- Female
- Hong Kong
- Humans
- Lopinavir
- Male
- Middle Aged
- Poisson Distribution
- Pyrimidinones
(therapeutic use)
- Retrospective Studies
- Ritonavir
(therapeutic use)
- Severe Acute Respiratory Syndrome
(drug therapy)
- Treatment Outcome
|